Loading...
•
Jun 30, 2025
TG Therapeutics Q2 2025 Earnings Report
TG Therapeutics reported strong Q2 2025 results with significant revenue growth driven by BRIUMVI sales.
Key Takeaways
TG Therapeutics saw substantial growth in Q2 2025, led by U.S. BRIUMVI sales totaling $138.8M, contributing to $141.1M in total revenue and $28.2M in net income.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
TG Therapeutics raised full-year BRIUMVI U.S. net revenue guidance to $570–575M and total global revenue target to approximately $585M.
Positive Outlook
- Raised 2025 BRIUMVI U.S. net revenue guidance to $570–575M
- Updated global revenue target to $585M
- Strong sales momentum and physician confidence in BRIUMVI
- Ongoing expansion outside U.S. with multiple regulatory approvals
- Progress in ENHANCE trial and new subcutaneous formulation
Challenges Ahead
- Increased R&D and SG&A expenses year-over-year
- No adjusted EPS reported
- Revenue concentration heavily reliant on a single product
- Risks from future regulatory or safety developments
- Dependence on sustained BRIUMVI uptake for guidance achievement
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...